| Gefisol 250 mg | |
| Active ingredient | Gefitinib |
| Brand | Gefisol 250 |
| Country of origin | India |
| Form | Oral tablets |
Gefisol 250 mg is a targeted anticancer medication used to treat certain types of non-small-cell lung cancer (NSCLC), particularly those associated with specific mutations in the epidermal growth factor receptor (EGFR) gene.
Clinical Uses
The following are the uses of Gefisol 250 mg:
- It is used to treat certain types of non-small-cell lung cancer (NSCLC). It is a condition in which cells multiply in an uncontrolled and abnormal manner in lung tissues
- This medication is particularly effective in patients with specific mutations in the epidermal growth factor receptor gene.
- It helps inhibit cancer cell growth and proliferation by blocking EGFR tyrosine kinase activity.
- Slows the progression of cancer in eligible patients.
- Helps to control the disease and improve symptoms in patients who respond to treatment.
How It Works?
Gefisol 250 mg works by selectively binding to the ATP-binding site of EGFR and inhibiting its tyrosine kinase activity. It is an anilinoquinazoline derivative that interacts with a kinase inhibitor that inhibits an abnormal protein called the epidermal growth factor receptor (EGFR). This helps to slow or stop the growth of cancer cells and reduce the size of tumors in patients with NSCLC.
Side Effects
The following are the side effects of Gefisol 250 mg:
- Skin rash and acne-like eruptions.
- Weakness and fatigue.
- Dry skin and itching.
- Diarrhoea.
- Nausea and vomiting.
- Mouth sores or inflammation.
- Loss of appetite.
- Rare but serious interstitial lung disease, which may cause severe breathing difficulties.
- Elevated liver enzymes and potential liver toxicity.
- Eye irritation or conjunctivitis.
In case,the symptoms worsen, you should consult a doctor immediately.
Precautions & Warnings
- Liver function tests should be performed regularly, as gefitinib may cause liver toxicity.
- You can use with caution in patients with a history of interstitial lung disease. Seek immediate medical attention if new or worsening breathlessness, cough, or fever occurs.
- Severe or persistent diarrhoea may cause dehydration and require medical attention.
- Skin reactions: Monitor for severe skin rash, blistering, or peeling.
- Discuss the risks with a doctor before treatment; pregnancy should be avoided during treatment and for the recommended period afterward.
- Gefitinib should be taken only as prescribed by an oncologist, with regular monitoring of treatment response and adverse effects.
Drug Interactions
Medicines that might interact with Gefisol 250 mg:
- CYP3A4 inhibitors such as ketoconazole and itraconazole.
- CYP3A4 inducers: Drugs such as rifampicin, phenytoin, carbamazepine, and St. John’s wort.
- Acid-reducing agents: Proton pump inhibitors (e.g., omeprazole) and H₂-receptor antagonists.
- Anticoagulants: Warfarin may increase the risk of bleeding or changes in INR; close monitoring is recommended.
- Other anticancer medicines: Certain combinations may increase toxicity or affect treatment outcomes and require specialist supervision.
Always consult a doctor before taking any medication along with Gefisol 250 mg.
Disclaimer
At 5M Biotech India we provide accurate, reliable and expert reviewed information. However, all our content on this platform is intended for informational purposes only and is not professional medical advice, diagnosis or treatment. While we make efforts to maintain accuracy, the information may contain mistakes, omissions or may not reflect the latest developments. Always consult your doctor regarding any medical concerns.
All medicine names, trademarks, and registered trademarks displayed on 5M Biotech India are property of their respective owners. 5M Biotech India and its operator are not affiliated with, endorsed by or authorized by any such trademark owners unless stated expressly. Any reference to trademarks or product names is made for informational purposes. No sponsorship, commercial relationship, approval or association with any trademark owner should be inferred. Information provided herein does not constitute advertising, promotion or an offer for sale of any medicinal goods and is intended solely for general informational purposes.
